Hey Siri, can I get pregnant?

While we’re not quite to the level of checking with Siri on fertility, if you’re curious what your daily likelihood of pregnancy is—you guessed it—there’s an app for that. Natural Cycles, an app that’s recently been certified as a method of birth control by the EU, tracks daily fertility using a highly accurate thermometer to register body temperature combined with details on menstruation to suggest chance of pregnancy on any given day. The app is the first of its kind to receive approval from a European health agency as a legitimate contraceptive and is an updated version of tracking fertility through a calendar. While conventional birth control is still more effective, the app does offer a natural alternative to better plan for or avoid pregnancy.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Clinical trial participation – from the comfort of home

In the age of Amazon Prime, grocery delivery, and, yep, even sock delivery subscriptions, it’s getting easier and easier to never leave the house. And it’s even more annoying when you do have to venture out and interact with other human beings, amirite? Luckily for us hermits, PAREXEL and Sanofi aim to make it easier to participate in clinical trials from the comfort of your Lazy Boy. The two companies are launching a pilot study to test the medical and scientific viability of wearable devices in clinical trials using PAREXEL’s patient sensor solution. The goals are to make things easier on patients and sites, collect a whole bunch of data, and reduce costs all the way around. High five for progress!

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Sayonara, sticking?

People with Type 1 diabetes could soon be saying goodbye to sticking their fingers to check blood sugar levels. This news comes from a study among children with Type 1 diabetes conducted by the University of Virginia, that tested how well an artificial pancreas developed by the school performed at managing insulin and glucose levels against the patient’s home routine. The platform, which is controlled using a smartphone, uses algorithms that wirelessly link to a blood-sugar monitor and insulin pump worn by the patient, as well as to a remote-monitoring site. The children using the device averaged more time within the target blood-sugar range without an increase in hypoglycemia than those without. Also, probably no need to worry about getting kids to check their phones.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Apple’s top secret plan for diabetes

A secret team at Apple, made up of around 30 tech and biomedical experts, is working on a program that would use the Apple Watch as a sensor “that can noninvasively and continuously monitor blood sugar levels to better treat diabetes,” according to three bean-spillers close to the project. This was envisioned by Apple co-founder Steve Jobs prior to his death. The project has been ongoing for at least five years, and is reportedly run now by Apple’s SVP of hardware technologies, Johny Srouji. How would something like this work? Good question. According to a CNBC article, the program would “[shine] a light through the skin to measure indications of glucose.” It’s like something Q would create – for a diabetic 007.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

5. Alexa, what’s my blood sugar?

Alexa could be preparing to handle that question and many more from people with diabetes following a partnership between Merck and Amazon Web Services. The two companies will work alongside Luminary Labs to run a challenge focused on using Amazon Echo’s voice-enabled software to assist those with diabetes, with the long-term hope of expanding to other chronic illnesses. The Echo, which is set to sell around 110 million devices over the next four years, may have utility in the future that’s beyond playing your favorite song or telling you the weather. With the help of developers, it could morph into a tool used to remind people of their nutrition plans or schedule their upcoming insulin dosages.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

3. A test to get rid of the c-word

Cancer…the c-word is cancer. Grail, a Silicon Valley startup, is developing a blood test similar to a liquid biopsy that works proactively to spot cancer. According to Business Insider, the goal is to “identify the tiny bits of cancer DNA that are hanging out in our blood but are now undetectable.” A test like that will take time, massive clinical trials and, of course, money. Lucky for them, Grail just raised more than $900M in funding from big names like Johnson & Johnson Innovation, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings Limited, Varian Medical Systems, and even Amazon. Who knows, maybe Prime members can get test results delivered to their front door in less than two business days.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

1. I was told there would be no math

People in the US are living longer (and elsewhere, too, surely). Healthcare spending in the US is expected to increase from 5.5% of the economy today to almost 9% by 2046. But why? With most healthcare spending occurring in the last five years of life, that spending is fixed, and an increasing life expectancy should just push that spending out a few years. Several studies suggest that technology is a major cause of healthcare spending increases, accounting for as much as one-third to two-thirds of the increase. And technology, while good, is expensive. Just ask someone with a heart condition or ask a premature baby how technology helped them. They can answer because they’re still alive. That’s right. Our premature baby talks. So?

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn